(Q50654258)

English

Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial.

scientific article published on 17 March 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/24636483

Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/24636483

0 references

1 reference

based on heuristic

inferred from title

author name string

Francisco Romo-Nava

1

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/24636483

Dení Alvarez-Icaza González

2

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/24636483

Ana Fresán-Orellana

3

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/24636483

Ricardo Saracco Alvarez

4

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/24636483

Claudia Becerra-Palars

5

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/24636483

Julia Moreno

6

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/24636483

Martha P Ontiveros Uribe

7

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/24636483

Carlos Berlanga

8

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/24636483

Gerhard Heinze

9

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/24636483

Ruud M Buijs

10

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/24636483

publication date

17 March 2014

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/24636483

Bipolar Disorders

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/24636483

16

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/24636483

4

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/24636483

410-421

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/24636483

Prediction of real-world functional disability in chronic mental disorders: a comparison of schizophrenia and bipolar disorder.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

A meta-analysis of the efficacy of second-generation antipsychotics

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Schizophrenia practice guidelines: international survey and comparison.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Cardiovascular disease and metabolic risk factors in male patients with schizophrenia, schizoaffective disorder, and bipolar disorder.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Excess mortality of schizophrenia. A meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Cardiovascular risk in patients with bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Melatonin reduces body weight gain and increases nocturnal activity in male Wistar rats.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Melatonin: Nature's most versatile biological signal?

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Melatonin receptors: molecular biology of a new family of G protein-coupled receptors

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Sleep and circadian rhythms: key components in the regulation of energy metabolism

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Melatonin in mood disorders

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Role of melatonin on diabetes-related metabolic disorders

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Sleep and circadian rhythm disruption in psychiatric and neurodegenerative disease

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Sleep and circadian rhythm disruption in schizophrenia

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Circadian rhythms and sleep in bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Prevalence of metabolic syndrome in bipolar patients initiating acute-phase treatment: a 6-month follow up.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

The characteristics of sleep in patients with manifest bipolar disorder, subjects at high risk of developing the disease and healthy controls.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Attention and non-REM sleep in neuroleptic-naive persons with schizophrenia and control participants.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Alterations of melatonin receptors MT1 and MT2 in the hypothalamic suprachiasmatic nucleus during depression.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Organization of circadian functions: interaction with the body

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Melatonin generates an outward potassium current in rat suprachiasmatic nucleus neurones in vitro independent of their circadian rhythm

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Selective parasympathetic innervation of subcutaneous and intra-abdominal fat--functional implications

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Melatonin and the metabolic syndrome: physiopathologic and therapeutical implications

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Effects of melatonin and zinc on lipid profile and renal function in type 2 diabetic patients poorly controlled with metformin.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Melatonin effect on rat body weight regulation in response to high-fat diet at middle age.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Photoperiodic control of seasonal body weight cycles in hamsters

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Lithium- and valproate-induced alterations in circadian locomotor behavior in Drosophila

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Effect of lithium on the circadian rhythms of locomotor activity and glycogen synthase kinase-3 protein expression in the mouse suprachiasmatic nuclei

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Lithium lengthens the circadian period of individual suprachiasmatic nucleus neurons

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12196

21 January 2018

Identifiers

10.1111/BDI.12196

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/24636483

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/24636483

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50654258&oldid=1202677907"